Camurus AB (publ) (CAMRF)
USD 59.98
(-3.11%)
USD 59.98
(-3.11%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 13.61 Million SEK | -18.21% |
| 2022 | 16.64 Million SEK | -12.06% |
| 2021 | 18.92 Million SEK | -7.17% |
| 2020 | 20.38 Million SEK | -11.12% |
| 2019 | 22.93 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 12.16 Million SEK | 0.0% |
| 2024 Q2 | 10.59 Million SEK | 0.0% |
| 2023 Q4 | 13.61 Million SEK | -8.24% |
| 2023 FY | 13.61 Million SEK | -18.21% |
| 2023 Q1 | 14.76 Million SEK | -11.28% |
| 2023 Q2 | 16.42 Million SEK | 11.26% |
| 2023 Q3 | 14.83 Million SEK | -9.69% |
| 2022 Q1 | 17.26 Million SEK | -8.77% |
| 2022 FY | 16.64 Million SEK | -12.06% |
| 2022 Q3 | 17.36 Million SEK | 11.28% |
| 2022 Q4 | 16.64 Million SEK | -4.13% |
| 2022 Q2 | 15.6 Million SEK | -9.65% |
| 2021 Q4 | 18.92 Million SEK | -4.86% |
| 2021 Q3 | 19.89 Million SEK | 11.53% |
| 2021 FY | 18.92 Million SEK | -7.17% |
| 2021 Q1 | 19.11 Million SEK | -6.22% |
| 2021 Q2 | 17.83 Million SEK | -6.71% |
| 2020 Q3 | 18.62 Million SEK | -10.06% |
| 2020 FY | 20.38 Million SEK | -11.12% |
| 2020 Q2 | 20.7 Million SEK | -5.18% |
| 2020 Q1 | 21.83 Million SEK | -4.8% |
| 2020 Q4 | 20.38 Million SEK | 9.47% |
| 2019 Q3 | 22.81 Million SEK | -3.47% |
| 2019 FY | 22.93 Million SEK | 0.0% |
| 2019 Q4 | 22.93 Million SEK | 0.54% |
| 2019 Q2 | 23.63 Million SEK | -3.36% |
| 2019 Q1 | 24.45 Million SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 8.26 Million USD | -64.727% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -7850.126% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -675.458% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -16916.25% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -5024.701% |
| CSL Limited | 11.23 Billion USD | 99.879% |
| Evofem Biosciences, Inc. | 8000.00 USD | -170062.5% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -8998.747% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | 32.981% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | 34.894% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -23113.738% |
| Mesoblast Limited | 100.29 Million USD | 86.427% |
| Marizyme, Inc. | 667.12 Thousand USD | -1940.535% |
| Genus plc | 228.2 Million USD | 94.035% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 91.805% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -246870.247% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -515.973% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -870.324% |
| IMV Inc. | 27.39 Million USD | 50.315% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -150.862% |
| MultiCell Technologies, Inc. | 36.43 USD | -37367454.214% |
| ONE Bio Corp. | 592.19 Thousand USD | -2198.724% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 75.521% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -511.545% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1008.225% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -2354.606% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -53708.451% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -617.052% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -4127.64% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -8975.333% |
| Enzolytics Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -8190.247% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | 11.339% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -305398.205% |
| Genscript Biotech Corporation | 287.12 Million USD | 95.259% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -10678.135% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -5836.997% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -5826.658% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -1279317.293% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -8998.747% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -9554.61% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -74.08% |
| SYBLEU INC | 300 Thousand USD | -4437.667% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -3588.67% |
| International Stem Cell Corporation | 445 Thousand USD | -2959.101% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -67.031% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -2878.775% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -1072.524% |
| PureTech Health plc | 18.25 Million USD | 25.408% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -8975.333% |
| IXICO plc | 275 Thousand USD | -4850.182% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -14.984% |
| Gelesis Holdings, Inc. | 26.3 Million USD | 48.257% |
| CSL Limited | 11.23 Billion USD | 99.879% |
| Cellectis S.A. | 36.21 Million USD | 62.407% |